Medical Patent News RSS Feed - Medical Patent News

eAgile receives patent for eSeal RFID-enabled packaging solution

eAgile Inc., a global leader in radio frequency identification (RFID) technologies, announced today that the U.S. Patent Office has granted a patent for the company's eSeal RFID-enabled packaging solution. [More]
Genticel provides update on patents granted in the USA and Asia

Genticel provides update on patents granted in the USA and Asia

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, provides an update on patents that have recently enriched its intellectual property estate. [More]
Actavis seeks FDA ANDA approval for generic Zubsolv, confirms patent challenge

Actavis seeks FDA ANDA approval for generic Zubsolv, confirms patent challenge

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Actavis' ANDA product is a generic version of Orexo's Zubsolv, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence. [More]
Perrigo, Catalent settle Proair HFA patent case with Teva

Perrigo, Catalent settle Proair HFA patent case with Teva

Perrigo Company plc and its partner, Catalent, announced today that they have settled their first to file Hatch Waxman litigation with Teva with respect to a generic version of Proair HFA. [More]
BioLineRx gets Notice of Allowance for patent related to new treatment for celiac disease

BioLineRx gets Notice of Allowance for patent related to new treatment for celiac disease

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent claiming the composition of BL-7010, a novel polymer for the treatment of celiac patients. [More]

Charter Communications, Spherix reach agreement to dismiss action filed on Jan 17, 2014

Spherix Incorporated -- an intellectual property development company committed to the fostering and monetization of intellectual property, today announced that Spherix and Charter Communications, Inc., Wideopenwest Finance LLC a/k/a Wow! Internet, Cable & Phone, Knology, Inc., Cequel Communications, LLC, d/b/a Suddenlink Communications, and Cable One, Inc., (collectively "Plaintiffs") filed a joint stipulation of dismissal in the action filed on January 17, 2014. [More]
USITC rules out patent claims on Apex's CPAP-complimentary mask

USITC rules out patent claims on Apex's CPAP-complimentary mask

Apex Medical Corporation a leading player in the Respiratory Therapy and Pressure Area Care sectors, announced that it has successfully obtained an initial advisory opinion from the United States International Trade Commission (USITC) that its continuous positive airway pressure (CPAP)-complimentary mask product is free from patent claims previously asserted by its Australia-based competitor, ResMed. [More]
Actavis signs deal with Cephalon to settle patent litigation related to Nuvigil tablets

Actavis signs deal with Cephalon to settle patent litigation related to Nuvigil tablets

Actavis plc today announced that it has entered into an agreement with Cephalon, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Nuvigil® (armodafinil tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg). [More]
USPTO grants two additional patents to SeroVital-hgh formula

USPTO grants two additional patents to SeroVital-hgh formula

SeroVital®-hgh, the "Fountain of Youth" Formula everyone's talking about, has been making headlines ever since a group of some of the most renowned researchers in the world revealed that this oral compound is actually capable of increasing mean, endogenous, serum (blood) human growth hormone (hGH) levels by 682%. Experts everywhere — from dermatologists and obesity researchers to women's healthcare providers and even the famed Dr. Oz himself — began paying attention to this groundbreaking formula. [More]
OxThera granted new patents for treatment of hyperoxaluria

OxThera granted new patents for treatment of hyperoxaluria

OxThera AB announced today that it has been granted two new US patents and one new Australian patent during the last year. [More]
Baylor receives patent for islet cell transplantation in patients with type1 diabetes, chronic pancreatitis

Baylor receives patent for islet cell transplantation in patients with type1 diabetes, chronic pancreatitis

Baylor Research Institute has been awarded a patent from the U.S. Patent Office for a potential strategy to improve the outcomes of islet cell transplantation for patients with type 1 diabetes and chronic pancreatitis. [More]
Three NSU professors secure patents for their innovations

Three NSU professors secure patents for their innovations

Three Nova Southeastern University's (NSU) professors from three different colleges recently secured patents for their innovations. [More]
USPTO issues three new patents to Discovery Laboratories

USPTO issues three new patents to Discovery Laboratories

Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, today announced that the United States Patent and Trademark Office (USPTO) has issued a new patent and Notices of Allowance for patents covering critical aspects of its KL4 surfactant and drug delivery technology platform. [More]
TWi and Endo Pharmaceuticals settle patent litigation over Lidoderm product

TWi and Endo Pharmaceuticals settle patent litigation over Lidoderm product

TWi Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Endo Pharmaceuticals Inc., Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. to settle all outstanding patent litigation related to TWi's lidocaine topical patch 5% product. [More]
Top performing oncology drugs at risk of losing patent rights by 2022

Top performing oncology drugs at risk of losing patent rights by 2022

After a period of relative stability, a glut of patent expiries is just five years away for the oncology market, according to pharmaceutical analyst Datamonitor Healthcare. [More]
Federal district court enforces settlement between Mylan and Endo Pharmaceuticals on generic FROVA

Federal district court enforces settlement between Mylan and Endo Pharmaceuticals on generic FROVA

Mylan Inc. today confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for Frovatriptan Succinate Tablets, 2.5 mg. [More]

LifeBond granted Chinese patent for novel absorbable surgical adhesive technology

LifeBond Ltd., a leading developer of absorbable biosurgical products for tissue repair, announced today that the State Intellectual Property Office of the People's Republic of China has granted the company its first Chinese patent. [More]
USPTO grants patent for low-cost dry powder inhaler to Hovione

USPTO grants patent for low-cost dry powder inhaler to Hovione

Hovione announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for a capsule-based, low-cost dry powder inhaler (DPI) to Hovione. This happened less than three years after the patent was filed and after just one Office Action - unusual speed for an inhaler application. [More]
U.S. Supreme Court agrees to hear Teva Pharmaceutical's appeal related to COPAXONE patent

U.S. Supreme Court agrees to hear Teva Pharmaceutical's appeal related to COPAXONE patent

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that the U.S. Supreme Court has granted the Company's COPAXONE® certiorari petition and will hear its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 (the "'808 patent"). [More]
Actavis gets favorable ruling in patent suit against generic Lialda

Actavis gets favorable ruling in patent suit against generic Lialda

Actavis plc today confirmed that the United States Court of Appeals for the Federal Circuit has reversed a lower court ruling that Actavis' generic version of Shire's Lialda (mesalamine extended-release tablets) infringes United States Patent No. 6,773,720 (the '720 Patent). [More]